Abstract:As a promising radiotherapy technology, stereotactic body radiotherapy (SBRT) enables precise delivery of high-dose radiation in a short course. The characteristic of SBRT is that a high dose outside the target area decreases rapidly, which can ensure the therapeutic dose of the target area and can also minimize the exposure dose of the organ at risk around the target area when compared with regular radiotherapy. Currently, SBRT has become an effective treatment for early stage NSCLC especially for older patients when they are not suitable for operation. We have read with interest this article by Moreno et al.1Moreno A.C. Fellman B. Hobbs B.P. et al.Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage NSCLC.J Thorac Oncol. 2020; 15: 101-109Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar about the optimal dose for SBRT in patients with early NSCLC. Moreno et al.1Moreno A.C. Fellman B. Hobbs B.P. et al.Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage NSCLC.J Thorac Oncol. 2020; 15: 101-109Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar investigated a large cohort with over 20,500 patients. They found that 5-year overall survival (OS) rates were 26% for low biologically effective dose (BED) (BED10 < 130 Gy) and 34% for high BED (BED10 ≥ 130 Gy) groups (p = 0.039), suggesting that a BED10 of 130 Gy and above may confer an additional survival benefit. We would like to point out some concerns regarding this article. First, the authors should consider the competitive risk relationship between cancer-caused death and noncancer-caused death, which is highly related to age. In this article, 70% of patients are more than 70 years old. Thus, noncancer-caused death could be the primary reason for the death toll. Second, we wonder whether the age range was well-balanced between the low-BED and high-BED groups, because the authors only divided patients into two groups (age <70 y and age ≥70 y). We believe that the authors should perhaps need to divide the age into more stratifications (such as <70 y, 75–80 y, 80–85 y, >85 y) or consider the age as a continuous variable in propensity-score matching. Recent studies revealed that SBRT, combined with other treatments, was associated with improved survival. Grinnell et al.2Grinnell M. Appiah A.K. Baine M. et al.Adjuvant chemotherapy following SBRT for early stage non-small cell lung cancer (NSCLC) in older patients [e-pub ahead of print]. J Geriatr Oncol.https://doi.org/10.1016/j.jgo.2020.04.014Google Scholar found adjuvant chemotherapy after SBRT was associated with improved OS in patients more than 70 years old with tumors greater than or equal to 4 cm2. SBRT and immune checkpoint inhibition are rapidly growing and effective treatment modalities.3Käsmann L. Eze C. Manapov F. Stereotactic body radiation therapy (SBRT) combined with immune check-point inhibition (ICI) in advanced lung cancer: which metastatic site should be irradiated to induce immunogenic cell death?.Int J Radiation Oncol Biol Phys. 2020; 108: 225-226Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar In the randomized phase 2 study (PEMBRO-RT) trial, compared with pembrolizumab, SBRT followed by pembrolizumab revealed a doubling of the OS (15.9 mo versus 7.6 mo) and objective response rate (36% versus 18%) in advanced NSCLCs.4Theelen W.S.M.E. Peulen H.M.U. Lalezari F. et al.Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial.JAMA Oncol. 2019; 5: 1276-1282Crossref PubMed Scopus (243) Google Scholar These combinations greatly expand the application range of SBRT. As the population ages, there will be a higher proportion of patients who are suitable for SBRT. Therefore, SBRT is a promising method for future clinical applications.

Stereotactic body radiotherapy of lymph node metastases under MR-guidance: First clinical results and patient-reported outcomes

High-risk patients with locally advanced non-small cell lung cancer treated with stereotactic body radiation therapy to the peripheral primary combined with conventionally fractionated volumetric arc therapy to the mediastinal lymph nodes

Clinical Outcomes of Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Adrenal Metastases from a Single Institution

Clinical Outcomes of Prostate SBRT Using Non-adaptive MR-Guided Radiotherapy

Full Dose SBRT in Combination With Mediastinal Chemoradiation for Locally Advanced, Non-Small Cell Lung Cancer: A Practical Guide for Planning, Dosimetric Results From a Phase 2 Study, and a Treatment Planning Guide for the Phase 3 NRG Oncology LU-008 Trial

Clinical Outcomes After Stereotactic Body Radiation Therapy for Nonspinal Bone Metastases: A Systematic Review and Meta-analysis

Stereotactic body radiation therapy and thermal ablation for treatment of NSCLC: A systematic literature review and meta-analysis

MR-guided online adaptive stereotactic body radiotherapy (MRgSBRT) of primary lung tumors and lung oligometastases

Clinical outcomes of patients with unresectable primary liver cancer treated with MR-guided stereotactic body radiation Therapy: A Six-Year experience

P3.16-19 Clinical Outcomes of Stereotactic Body Radiation Therapy for T2N0M0 Non-Small Cell Lung Cancer

The Critical Role of Stereotactic Body Radiation Therapy in Multimodal Treatment of Lung Metastasis from Bone and Soft Tissue Sarcomas

Early and repetitive novel-tracer PET-guided stereotactic body radiotherapy for nodal oligorecurrent prostate cancer after definitive first-line therapy

Long-term outcomes of metastasis-directed stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma

Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer – A phase II study

LBA60 Stereotactic Body Radiation Therapy with Sequential Immunochemotherapy As Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer

Stereotactic Body Radiation Therapy for Post-Pulmonary Lobectomy Isolated Lung Metastasis of Thoracic Tumor: Survival and Side Effects

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions

Promising Stereotactic Body Radiotherapy in NSCLC

[Prognosis Analysis of Early-stage Non-small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy]

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer

Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research